At a glance
ClinicalIndex Comparison RecordPhase 3Active· 453 enrolled
Drug / intervention
MRTX849 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Phase 3 Study of MRTX849 Versus Docetaxel in Patients With Previously Treated Non-Small Cell Lung Cancer With KRAS G12C Mutation
In Brief
A Phase 3 clinical trial evaluating MRTX849 and Docetaxel for Metastatic Non Small Cell Lung Cancer and Advanced Non Small Cell Lung Cancer. Active but no longer recruiting, targeting 453 participants across 343 sites in 23 countries.
Detailed Summary
This Phase 3 study will evaluate the efficacy of the investigational agent MRTX849 (adagrasib) versus docetaxel in patients who have been previously treated for metastatic NSCLC with a KRAS G12C mutation.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesAustralia, Austria, Belgium, Czechia, France, Germany, Greece, Hong Kong, Hungary, Ireland, Italy, Netherlands, Poland, Portugal, Puerto Rico, Romania, Russia, Singapore, South Korea, Spain, Switzerland, United Kingdom, United States
Collaborators--
Timeline
Phase 3ActiveOverdue
202120222023202420252026
First PostedDec 2020
Enrollment StartFeb 2021
Primary CompletionDec 2023
Study CompletionJul 2026
TodayJul 2026
First PostedDec 28, 2020
Enrollment StartFeb 23, 2021
Primary CompletionDec 30, 2023
Study CompletionJul 2, 2026
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 5.5 years ago
Interventions
MRTX849drug
21 day cycles
Docetaxeldrug
21 day cycles